Rituximab for the Treatment of Refractory Cardiac Sarcoidosis –A Single Center Experience

Cardiac involvement is one of the leading causes of death related to sarcoidosis [1]. However, information regarding effective management is limited and the consequences of cardiac sarcoidosis (CS) can be devastating, with these individuals often progressing to the requirement of cardiac transplantation [1]. Research thus far into this rare, but increasingly prevalent (20-fold increase in annual detection along the past 25 years) [1], disease is limited and currently has not allowed for generation of an evidence-based algorithm for treatment [2].

Source: Journal of Cardiac Failure - July 24, 2021 Category: Cardiology Authors: Mohamed Elwazir, Megan L. Krause, John P. Bois, Georgios Christopoulos, Ayse T. Kendi, Jr. Leslie T. Cooper, Hayan Jouni, Omar F. AbouEzzeddine, Panithaya Chareonthaitawee, Mohamed Abdel Shafee, Shreyasee Amin Source Type: research